Click here for Great Britain and Northern Ireland Prescribing Information for MYLOTARG®▼ (gemtuzumab ozogamicin) and cytarabine.
Adverse event reporting information can be found at the bottom of the page.
PubExplainer videos
Three animated videos which explain in a clear and succinct way:
- Mechanism of action and the fractionated dosing schedule for MYLOTARG
- The key data from the Phase III ALFA-0701 study
- Measurable residual disease (MRD) and why it matters
Mechanism of action and the Fractionated dosing schedule for MYLOTARG
A short video (3.03 duration) explaining
-MYLOTARG's mechanism of action
-Leading to the rationale of MYLOTARG's fractionated dosing schedule
-The resulting efficacy and safety data from the ALFA-0701 study
-Summary of the NICE recommendation
ALFA-0701 study
A quick video (03.26 duration) that covers all the key points related to the pivotal Phase III ALFA-0701 study
- Study Design
- Baseline characteristics
- Induction and Consolidation courses
- Primary endpoint: Event Free survival results by cytogenetic group
- Secondary endpoint: Relapse Free Survival results
- Adverse Events reported
What is MRD and why does it matter?
This video (3.33 duration) aims to illustrate the concept of MRD by aggregating findings from different disease areas, studies and results. Its main focus is on Acute Lymphoblastic Leukaemia and data on Acute Myeloid Leukaemia is shown at time point 2.40.
This video covers:
-Definition of MRD
-Detection
-Principles
-Relevance: Complete remission
-Impact on Survival rates and patient outcomes
Explore more
Download the fast facts PDF document to aid your understanding of MYLOTARG
Download the pdf
AML, Acute Myeloid Leukaemia; MRD, measurable residual disease
Register to receive tailored marketing information from Pfizer by email
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
Quick Links
Understand the evidence
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?